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Aim: In this work, a graphical method for radiotherapy treatment plan assessment and com-parison, named SPIDERplan, is 
proposed. It aims to support plan approval allowing indepen-dent and consistent comparisons of different treatment techniques, 
algorithms or treatment planning systems.
Background: Optimized plans from modern radiotherapy are not easy to evaluate and com-pare because of their inherent 
multicriterial nature. The clinical decision on the best treatment plan is mostly based on subjective options.
Materials and methods: SPIDERplan combines a graphical analysis with a scoring index. Customized radar plots based on the 
categorization of structures into groups and on the determination of individual structures scores are generated. To each group and 
structure, an angular amplitude is assigned expressing the clinical importance deﬁned by the radiation oncologist. Completing the 
graphical evaluation, a global plan score, based on the structures score and their clinical weights, is determined. After a necessary 
clinical validation of the group weights, SPIDERplan efﬁcacy, to compare and rank different plans, was tested through a planning 
exercise where plans had been generated for a nasal cavity case using different treatment planning systems.
Results: SPIDERplan method was applied to the dose metrics achieved by the nasal cavity test plans. The generated diagrams 
and scores successfully ranked the plans according to the prescribed dose objectives and constraints and the radiation oncologist Keywords: Plan approval support ; Plan scoring; Treatment planning; Radiation therapy
priorities, after a necessary clinical validation process.
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a. Background
adiotherapy is a treatment cancer modality that has as main
urpose to eliminate tumour cells in a controlled way through
adiation, while sparing as much as possible adjacent nor-
al tissues. Each treatment session is delivered according to
n optimized plan generated by a treatment planning system
TPS). The selection of the plan whose dose distribution bet-
er fulﬁls the medical prescription is not a trivial task. Visual
nspection of the 3D dose distribution, a detailed analysis of
he dose statistics and dose volume histograms (DVH) gener-
ted for each structure are the most common tools to assess
he quality of the plan. To assist the radiation oncologist in
lan selection, several graphical solutions, such as the super-
osition ofDVHanddose distributions or the side-by-side plan
omparison, have been made available in commercial TPSs.
he large and diverse amount of data to be analyzed, gener-
lly with conﬂicting results, makes plan selection hard and
ime-consuming. Final clinical decision is then made by the
adiation oncologist mostly based on a subjective and qualita-
ive assessment of the planned dose distributions taking into
ccount only the most important features of the plan.1 Opti-
al balance between the probability of tumour control and
ormal tissues complications is thusnot guaranteedmoreover
hen multiple plans are available for ﬁnal clinical decision.
uantifying plan quality taking into account both the cov-
rage of target volumes and the sparing of all organs-at-risk
OAR) in a simple and objective way has always been an ideal
im in the treatment planning process for helping the ﬁnal
linical decision. First attempts have been proposed based on
tatistical decision theory,2 multiattribute utility theory3 and
ecision analysis concepts3 for application to 3D conformal
adiotherapy. However, they have never been incorporated in
ptimization algorithms nor implemented in treatment plan-
ing systems.
On the other hand, dose-quality treatment indexes have
een considered a valuable contribution for plan assessment.
ince the 1990s, several indexes have been reported for exter-
al radiotherapy.4–20 Target coverage and conformity indexes
re the most common options. Target coverage index, known
s RTOG index, ﬁrst proposed by Shaw et al.4 for radiosurgery
reatment planswas intended tomeasure the ratio of themin-
mum isodose to the prescribed dose in the planning target
olume (PTV). Despite its simplicity, the coverage index yields
alse positives and is extremely dependent of the selected ref-
rence isodose. A different coverage target scorewas proposed
y the SALT group5,6 and by Lomax and Scheib.7 Based on a
olumetric concept, this approach solves the previous draw-
acks, but as for the RTOG index, it still does not take into
ccount dose in the healthy tissues. Conformity indexes focus
n the relation between the shape of the reference isodose
nd the PTV. Although the ﬁrst conformity index types weredeveloped for the evaluation of radiosurgery plans, Knöös
et al.9 extended this deﬁnition to breast, lung, prostate and
head-and-neck pathologies. Simple as they are, these indexes
neither consider the dose received by the normal tissues nor
distinguish spatial mismatches between the target volume
and the reference dose volume. Lomax and Scheib7 presented
a conformity index deﬁnition that includes the quantiﬁcation
of the irradiation of healthy tissues. To avoid false posi-
tives, this index should be reported together with the target
coverage index also proposed by Lomax and Scheib.7 The con-
formation number (CN), proposed by van’t Riet et al.10 and
Paddick,11 intended to assess the conformity of a radiosurgery
plan, quantifying target coverage and normal tissues expo-
sure. However, the CN score does not take into account the
different OAR tolerances, considering all non-tumour tissues
as a single critical structure with the same radiosensitivity.
Thiswas partially solved by the COIN score, initially developed
for brachytherapy plans.12 The COIN added to the CN expres-
sion a penalty factor for the unwanted doses in the OAR. As
the dose values used in the score calculation are not adjusted
to the tolerance level of each structure, a new index called
critical organ scoring index (COSI) was proposed.13 The COSI
index allows a simultaneous quantiﬁcation of target coverage
and dose irradiation of OARs. To get information about plan
conformity, the COSI index must be represented in a 2D dia-
gram against the conformity index proposed by Lomax and
Scheib.7 The inclusion of both target coverage and OAR affec-
tation into CN, COIN and COSI deﬁnitions leads to a loss of
information allowing that different dose distributions may
present the same index values.
Based on the radiosurgery quality indexes, new score def-
initions applicable to all radiotherapy modalities have been
published, namely for intensity modulated radiation therapy
(IMRT) plans. Due to their comprehensive deﬁnition and appli-
cability, the uncomplicated target conformity index (TCI+),14
the conformity index incorporatingdose anddistance (CIDD),15
the plan quality index (PQI),16 and the composite quality index
(CPQI)17 are the most representative scores. The TCI+, sug-
gested byMiften et al.,14 includes adjustable penalty functions
evaluating target conformity and OARs sparing. Despite the
good results, the sensitivity of the parameters of the penalty
function depends on the clinical experience and the accu-
racy of the clinical tolerance data. A similar approach was
proposed by Cheung and Law15 with the CIDD. In addition
to the target coverage factor, this score also incorporates a
target underdosage factor that presents a penalty function
dependent on the value and localization of the cold spot.
Nevertheless, the CIDD neither quantiﬁes the normal tissue
sparing nor the conformity of the dose distribution to the
target. The PQI developed by Leung et al.16 incorporates mul-
tiple plan evaluation scores. Applying the Euclidean distance
deﬁnition to the conformity of PTVs with different dose lev-
els, target coverage and normal tissue sparing are assessed.
The PQI index also includes a quantiﬁcation of the cold and
hot spots in the target coverage parameter. The normal tissue
score includes a penalty function that allows the evaluation of
different tolerance point criteria. More recently, the compos-
ite quality index or CPQI17 combined the target coverage, the
homogeneity index, the equivalent uniform dose (EUD),21,22
tumour control probability (TCP) and the normal tissue com-
plication probability (NTCP) applying to each a relative weight.
Plan quality indexes are a promising solution for treatment
plan evaluation. However, due to their deﬁnition or complex-
ity, these tools were never widely adopted in clinical practice.
Using a completely different approach, alternative solu-
tions for treatment plan evaluation may be based on
radiobiological functions. TCP, NTCP and the probability of
uncomplicated tumour control23 are examples of radiobiolog-
ical measures that may estimate the outcome of a treatment
plan. However, nowadays, the beneﬁts that could be achieved
with this approach are still overshadowed by the uncertainty
associated with the variables needed during the biological
modelling process.
With the implementation of inverse treatment planning
optimization, a variety of objective functions were imple-
mented into TPSs to drive the optimization algorithm in each
iteration. The score corresponding to the value of the objective
function should ideally be correlated with the quality of the
dose distribution and, thus, the ﬁnal plan would represent the
optimal radiation treatment. Nevertheless, this is generally
a pure mathematical expression without clinical relevance.
Furthermore, a strict comparison between plans optimized in
different treatment planning systems is only valid when the
same objective function is used. Comparisons between dif-
ferent optimization algorithms are thus not generally made
simply based on the ﬁnal value of the objective function.
2. Aim
In this study a plan quality assessment tool called SPIDERplan
is proposed. This tool intends to evaluate the quality of dif-
ferent plans using an intuitive graphic representation and an
associated score function. These are based on the target and
normal tissues objectives/constraints deﬁned by the radiation
oncologist and are completely independent of the algorithm,
the treatment technique or the TPS. Without any ambition
to correlate this score with treatment outcome, SPIDERplan
aims to be a supporting tool to help during clinical decision-
making in consistently selecting the best treatment plan
available.
3. Material and methods
3.1. SPIDERplan concept description
SPIDERplan is a graphical method developed to assess and
compare thequality of different radiotherapy treatment plans.
Based on a scoring approach, both target coverage and indi-
vidual OAR sparing are considered, allowing the quantiﬁcation
of the global quality of any treatment planning modality. This
method can be described in two phases: 1) processing of the
plan data and 2) assessment of plan quality. The outputs forplan evaluation are graphs and scores that provide the user
with a fast and intuitive image of plan(s) quality. Clinical vali-
dation to ﬁne tune SPIDERplan input variables is necessary
before using it in clinical practice.
In phase one, processing of the plan data, targets and OARs
are divided into groups (e.g. optical track group, including
organs like optic nerves and chiasm). Each structure has an
assigned score basedonplanningobjectives thatmaybe either
dosimetric, volumetric, radiobiological or mathematical. This
score is a scalar that expresses the performance of that struc-
ture in accomplishing the corresponding planning goal. A
pre-deﬁned relativeweight is also attributed to each group and
to each structure expressing the clinical priorities during the
plan evaluation process. The deﬁnition of these groups and
weights must be customized by the local clinical team accord-
ing to the tumour type prior to the clinical use of SPIDERplan.
The numerical weighs reﬂect the relative importance given
by the radiation oncologist to the different planning aims.
Similarly, the grouping of the different structures strongly
depends on the tumour type and morphology and must
reﬂect the relative importance the physician will give to the
different structures when he/she will appreciate the dose
distributions. Thus, SPIDERplan is completely designed for
each tumour type according to the radiation oncologist’s
preferences.
In phase two, assessment of plan quality, all this infor-
mation is graphically represented in customized radar plots.
Evaluation of plan quality can be done globally visualizing all
structures and groups’ information or in more detail assessing
each group analysis in partial radar plots. For the global anal-
ysis mode, where all structures are considered, a radar plot
named Structures Plan Diagram (SPD) is generated. The circu-
lar plotting area is divided into sections and subsections with
an angular amplitude proportional to the relativeweight of the
respective group and structure. The score of each structure is
represented by a point along the angle bisector of the respec-
tive subsection whose distance from the centre of the radar
plot corresponds to the score value. By connecting the score
of all structures a polygon representing the quality of the dose
distribution is generated. Global plan score is determined as
a weighted sum of the structures individual scores across all
groups as:
Global plan score =
∑
i
∑
j
wgroup(i)wstruct(j)Scorestruct(j) (1)
where wstruct(j) and Scorestruct(j) are the relative weight and the
score of structure j, respectively, and wgroup(i) is the relative
weight of group i.
The SPD information may also be condensed by groups of
structures. In this option the radar plot is called Group Plan
Diagram (GPD), where it is designed for the groups instead of
the structures. A more detailed group evaluation can also be
done with the partial group plots. The group plots are named
Structures Group Diagrams (SGD). Only the structures of a par-
ticular group are then represented. As for the SPD and GPD, a
partial group score complementing the graphical assessment
is determined for each SGD.
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Table 1 – Groups and structures considered for
SPIDERplan processing.
Groups Structures
Name Name Tolerance criteria
PTV group PTV D98% ≥ 95% of 60Gy
Optics
group
Chiasm Dmax ≤ 50Gy
Left optical nerve (OPTNRVL) Dmax ≤ 50Gy
Right optical nerve (OPTNRVR) Dmax ≤ 50Gy
Left retina (RETINAL) Dmax ≤ 45Gy
Right retina (RETINAR) Dmax ≤ 45Gy
Left lens (LENSL) Dmax ≤ 12Gy
Right lens (LENSR) Dmax ≤ 12Gy
Other
group
Brainstem Dmax ≤ 54Gy
Pituitary gland (PITUITARY) Dmax ≤ 60Gy
Left cochlea (COCHLEAL) Dmean ≤ 45Gy
Right cochlea (COCHLEAR) Dmean ≤ 45Gy
F.2. Application to a clinical case
o assess SPIDERplan ability to compare and rank radiothe-
apy plans, an already treated nasal cavity clinical case was
elected and re-planned in iPlan RT Dose version 4.5 from
rainLAB. IMRT techniquewas based onanm3micromultileaf
ollimator (mMLC) from BrainLAB. For inverse optimization,
his TPS generates three IMRT plans with different OAR prior-
ties: low, medium and high. Irradiation technique used eight
on-coplanar beams composed of 15 segments. Dose calcula-
ion was done by applying a Pencil Beam algorithm and a dose
rid of 1× 1mm2.
SPIDERplan independence from TPS and dose calculation
lgorithms were assessed by comparing iPlan plans with a
lan generated in Oncentra version 4.1 SP2 optimizer mod-
le from Elekta for the same clinical case. The Oncentra IMRT
lan was generated using a Siemens 82-leaf Optifocus multi-
eaf collimator (MLC). Collapsed Cone algorithm with a dose
rid of 1× 1mm2 was applied to optimize 9 beams delivering
00 segments.
A dose of 60Gy delivered in 30 fractions was prescribed to
he PTV. Themain consideredOARswere lens, retinas, chiasm,
ptical nerves, pituitary gland, brainstem, cochlea, parotids
nd oral cavity. The respective tolerance doses values, shown
n Table 1, were established in agreement to the institutional
rotocols deﬁned for this pathology.
Structures were grouped into PTV group, Optics group and
ther group, Table 1. These groups were deﬁned according to
tructures localization and clinical importance for the pathol-
gy concerned. The PTV group just comprised the PTV. The
ptics group was constituted by all the optical structures:
ens, optical nerves, retinas and chiasm, which were next to
he PTV and so acted as critical structures for planning. The
ther group included all other structures that were distant
rom the PTV or whose tolerance dose values were not crit-
cal for this particular planning context: brainstem, pituitary
ig. 1 – Nasal cavity structures. Nasal cavity case CT images sliceOral cavity (ORALCAVITY) Dmean ≤ 45Gy
Left parotid (PAROTIDL) Dmean ≤ 26Gy
Right parotid (PAROTIDR) Dmean ≤ 26Gy
gland, cochlea, parotids and oral cavity (Fig. 1). This grouping
reﬂects the relative importance that the radiation oncologist
gives to the different structures when appreciating different
treatment options.
The score of each structuremaybedeterminedby any func-
tion locally used to evaluate plan quality. This study used a
score based on the ratio between clinical tolerance criteria and
the planned dose. Thus, a value of one is expected if the dose
for that structure is equal to the respective tolerance value.
When a better organ sparing or target coverage is achieved, a
score less than one will be obtained. In the SPIDERplan dia-
grams, this becomes easily perceived by the relation obtained
with two circles: the inner circle with unitary radius repre-
senting the limit of acceptability and the outer circle with
radius equal to two representing failures. Optimal scores will
converge to the radar plot centre.
s containing all the structures considered for planning.
For the PTV, the score was calculated according to the fol-
lowing expression:
ScorePTV =
DTC,PTV
DP,PTV
(2)
where DTC,PTV corresponds to the tolerance criteria for the PTV
(in this case the dose in 98% of the PTV that should be at least
95% of the prescribed dose) and DP,PTV is the planned dose in
the PTV. This is a target coverage criterion.
For the OARs, the score was set as:
ScoreOAR =
DP,OAR
DTC,OAR
(3)
where DP,OAR is the OAR planned dose and DTC,OAR is the
tolerance dose for each OAR. In this clinical example, the
score of each structure was based on the tolerances com-
monly used in our clinical practice corresponding to ICRU
Report 8324 planning aims. For some pathologies, there are
broad consensus guidelines (e.g. RTOG0615 for nasopharyn-
geal cancer). Yet, seldom will a radiation oncologist be able
to give the planner more than accepted tolerance doses for
OARs either expressed as maximum doses or mean doses in
a volume, considering more or less subjective values for the
probability of complications in a tissue while selecting treat-
ment plans. The plan is considered acceptable for treatment
when these criteria are met. In this study the function score
adopted compares the ratio between the prescription and the
planned dose. But this function serves just as an example.
SPIDERplan admits any type of score function as long as the
unity value separates admissible from inadmissible planning
aims. These deﬁnitions are not static and canbe customized in
any moment according to the clinician criteria and to the case
speciﬁcity.
3.3. SPIDERplan clinical validation
As SPIDERplan was developed to reﬂect the radiation oncol-
ogist criteria when he/she is approving a plan, a clinical
validation of the tool was performed prior to its appli-
cation. First, all plans were assessed and ranked by the
radiation oncologist using traditional tools: the DVHs, the
dose statistics and the dose distribution visualization, in a
completely independent way from SPIDERplan. To complete
clinical plan evaluation, the radiation oncologist classiﬁed the
plans as ‘Good’, ‘Admissible with minor deviations’ or ‘Not
admissible’.
To calibrate SPIDERplan to the radiation oncologist crite-
ria and preferences, a matrix, named here weight sensitivity
matrix, was determined. This matrix was calculated by vary-
ing theweights of all groups and considering all possible group
weights combinations. The weight of the group representing
the OAR was varied from 0% to 100% in steps of 10%. For
the PTV group the weight varied from 10% to 100% also in
steps of 10%. The set of group weights that better ﬁtted the
radiation oncologist evaluation was selected in SPIDERplan
processing.4. Results
4.1. SPIDERplan outputs
The proposed plan evaluation tool functionality and results
will be illustrated through the chosen nasal cavity clinical
case. SPIDERplan processing phase used the groups and struc-
tures deﬁned in Table 1, and the group clinical weights deﬁned
by the radiation oncologist.
The subsequent assessment phase for SPIDERplan gener-
ated different radar plots that can be analyzed by the planner
or the radiation oncologist. The SPD, GPD and SGD are shown
in Figs. 2 and 3.
From the SPD the best overall plan was the iPlan OAR
High (displayed polygon closer to the plot centre). By contrary,
Oncentra and the iPlan OAR Low plans were of lower qual-
ity. The diagram is complemented by the global score that
conﬁrms that the plan iPlan OAR High, with a global score
of 0.940, was the best dose distribution while the iPlan OAR
Low plan, with the score of 1.040, was the worst plan. GPD is
the condensed diagram showing the results for the groups. For
the nasal cavity tumour case the plan iPlan OAR High was the
only plan to achieve a global score equal or less than one for all
groups. iPlan OAR Medium and iPlan OAR Low obtained a poor
result for the Optics group and Oncentra for the PTV and the
Optics groups. As the global score is derived using the same
methodology in all diagrams, both radar plots may be used for
plan selection.
A more detailed analysis of plan quality can be done eval-
uating the score of each structure in a given group (Fig. 3).
For structures belonging to a group with just one element,
like the PTV group, this can be done directly in the Structures
Plan Diagram. For the PTV, the lowest score was achieved by
the iPlan OAR Low plan with a value of 0.959, followed by the
iPlan OAR High, Medium and the Oncentra plans with sco-
ring values of 0.969, 0.997 and 1.009, respectively. For larger
groups, a more comprehensive analysis can be performed by
visualizing the SGD (Fig. 3). For structures belonging to the
Optics group, iPlan OAR High was the only plan that accom-
plished all the clinical criteria (the red polygon is included
in the inner circle). By contrary iPlan OAR Low plan was
unable to achieve any of the clinical constraints for this group
(the green polygon is external to the unitary circle), pre-
senting the worst score values for the retinas and the lens.
For the optic nerves and the chiasm, the worst results were
obtained for the Oncentra plan (blue line). In general, for the
Optics Group diagram, the best plan scoring was achieved
by iPlan OAR High followed by iPlan OAR Medium, Oncentra
and iPlan OAR Low with group score values of 0.972, 1.003,
1.069 and 1.205, respectively. For the Other group, all plan opti-
mizations met the respective clinical criteria deﬁned for the
OARs in this group. The absolute value of these partial group
scores can just be used for relative comparisons within each
group.4.2. SPIDERplan clinical validation
Prior to SPIDERplan conﬁguration, the radiation oncologist
was asked to evaluate all iPlan and Oncentra plans using
Fig. 2 – Structures Plan Diagram and Group Plan Diagram. SPIDERplan Structures Plan Diagram and Group Plan Diagram
obtained for a nasal cavity tumour case. The solid rays of the diagram correspond to a structure and the dashed rays limit
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raditional tools (DVHs, planar dose distributions, etc.). The
esults are shown in Table 2. All plans were considered accept-
ble for treatment. iPlan OAR High was the plan that achieved
he best rank followed by the iPlan OAR Medium, Oncentra
ig. 3 – Structures Group Diagram. SPIDERplan Structures Group
roup, respectively.and iPlan OAR Low plans. All plans, with the exception of the
iPlan OAR High plan, were classiﬁed as ‘Admissible with minor
deviations’. iPlan OAR High plan was qualitatively evaluated
as ‘Good’.
Diagram generated for the Optics group and for the Other
Fig. 4 – Group weight sensitivity cluster. Cluster of combinations of group weight that produce the same plan ranking as the
radiation oncologist.
Table 2 – Clinical evaluation of the optimized IMRT plans
in iPlan and Oncentra.
Name Clinical plan assessment
Rank Qualitative classiﬁcation
iPlan OAR High 1 Good
iPlan OAR Medium 2 Admissible with minor deviations
Oncentra 3 Admissible with minor deviations
iPlan OAR Low 4 Admissible with minor deviations
To test the sensitivity of theweights needed for SPIDERplan
conﬁguration, the weight sensitivity matrix was calculated.
Fromall combinations of groupweights, the clusterwith those
weight combinations that maintained the plan ranking of the
radiation oncologist (Table 2) has been selected. Fig. 4 shows
the six combinations of group weights of this cluster clearly
illustrating that while the weights of the Optics group ranged
from 60% to 90%, the PTV group weights ranged from 10%
to 40% and the Other group weights ranged from 0% to 10%,
plan ranking remaining unchanged. In all six group weights
combinations, a common trend was veriﬁed: the Optics group
presented a higher weight than the PTV group and the Other
group. Furthermore, the weight assigned to each group is not
critical as there is a relatively large range where the quality of
the plans is sorted by SPIDERplan and the radiation oncologist
in the same way.
Using this analysis a robust weight assignment could be
done in SPIDERplan processing for the nasal cavity. The mean
values of the weight group ranges of the weight sensitivity
matrix were taken as: 75% for the Optics group, 20% for the
PTV group and for 5% the Other group.
5. Discussion
The ideal tool to support treatment plan evaluation would
be able to provide an objective measure identifying the
best treatment by quantitatively assessing the quality of the
dose distribution and consistently compare different plans.25
During the last two decades several proposals have beenpresented. Nevertheless, due to their complexity or concep-
tual limitations, no solution has been systematically adopted
by the radiation oncology community.
SPIDERplan was designed to be incorporated in a TPS as
one of the evaluation tools aiming to complement existing
ones and not to replace traditional plan evaluation methods,
like dose distribution visual inspection or DVH analysis. Mul-
ticriterial optimization and Pareto front navigation are eligible
applications of the proposed tool. In those environments, by
deﬁnition, a multiplicity of plans are to be considered. Along
with playing with a display tool for Pareto front navigation, as
described by Craft et al.,26 the physician could also have an
immediate picture of the whole set of plan possibilities in just
one graph. With the beneﬁt of having a complementary infor-
mation on the relative value of each plan according to his/her
own criteria.
The novelty of the proposed tool is not in the use of radar
plots. There are many examples in the literature of their
usage.27,28 The novelty of SPIDERplan is the way the radar plot
is built. By incorporating the clinical criteria deﬁned in dose
prescription, SPIDERplan becomes a graphical representation
of radiation oncologists’ viewpoints leading to plan approval.
With just one diagram, combined with a score index, the med-
ical team would be able to take decisions consistently when
comparing different plans. It is a simple idea using common
graphics to handle a difﬁcult problem. SPIDERplan intuitive
design allows a much faster decision in selecting the best
plan taking into account all structures.When the polygon runs
outside the inner circle (of radius one), dose objectives or con-
straints are surpassed and plan may be rejected. Otherwise,
the dose distribution fulﬁls dose prescription and tolerances
and the polygon with the smallest area indicates the best plan
available.
Treatment plan quality assessment performed by SPI-
DERplan can be applied to all pathologies, dose calculation
algorithms and delivery techniques. It incorporates the poten-
tial for customization for each radiation oncologist priorities
and criteria needed for plan approval. This is accomplished
by assigning in the processing phase a pre-deﬁned relative
w
t
d
s
o
N
p
a
c
r
p
m
e
t
t
t
A
i
r
s
b
r
r
i
S
a
e
t
e
g
s
e
a
w
A
i
t
a
a
p
q
s
a
c
a
a
a
r
o
s
1
S
c
p
r
i
i
t
r
conditions stéréotaxiques dans le groupe Salt.
Cancer/Radiotherapy 1998;2:127–38.
6. Dejean C, Lefkopoulos D, Foulquier JN, Schlienger M, Touboul
E. Déﬁnition automatique de l’isodose de prescription poureight to groups and structures that canbeadjustedaccording
o the case complexity or clinical demands. The score function
etermined for each structure is also conﬁgurable. Different
coring indexes based on traditional DVH information, or any
ther relevant physical or biological quantities like EUD, TCP,
TCP, etc.29 may be set up. This ﬂexibility confers to SPIDER-
lan the possibility to be easily adapted to new situations that
re recurrent in the clinical routine. For instance, some special
linical situationwhere a givenOAR should be given a stronger
elevance or the inclusion of a structure in the optimization
rocess that is not usually considered. For situations where
ixture of different types of planning goals are speciﬁed for
ach structure, the user can use composite scores16 or more
han one radius per structure in the SPIDERplan radar plot. For
he hot spots situations, a score including unspeciﬁed normal
issue (body minus PTVs) dose restriction may be included.
lso, some penalties to structure scores can be introduced
n order to point unacceptable deviations that would lead to
ejected plans.
The processing phase can be constructed on a class-
olution basis, like for instance some “wish-lists” that have
een proposed for optimization steering.30 All these tool
eﬁnements must be conducted in close collaboration with
adiation oncologists. Some time and effort needs to be
nvested in the pre-processing phase to clinically validate
PIDERplan for each tumour site. To adjust SPIDERplan plan
ssessment with the radiation oncologist evaluation is an
ssential step to enhance the conﬁdence and creditability in
his new tool. The proposed weight sensitivity matrix method
xpresses the clinical preferences for plan assessment and
ives a picture of the sensitivity of the clinical weights that
hould be used in the conﬁguration of SPIDERplan. This initial
ffort will be compensated by a much faster plan evaluation
nd treatment selection of similar clinical cases.
SPIDERplan potential to compare and rank treatment plans
as demonstrated in the chosen nasal cavity tumour case.
fter the clinical validation, the graphic information included
n the Structures Plan Diagram, the Group Plan Diagram and
he Structures Group Diagram enabled a fast and intuitive
ssessment of the quality of the dose distribution in the PTV
nd all OARs. To complement the diagrams evaluation, the
lan global score provided a quantitative measure of plan
uality. This measure was embedded in the SPIDERplan con-
truction, including both the score achieved by each structure
nd its relative importance according to the local or individual
linical reasoning. The new tool is independent from the TPS
nd the dose calculation algorithm. In a simple and system-
tic way it is possible to compare plans from different sources
nd consistently infer about their relative quality. The only
equirement is that the dose prescription, either in the form
f dose objectives or constraints, is the same. The number of
tructures in the presented clinical example was restricted to
5 (Table 1) but this number has no limitation. Although the
tructures Plan Diagram may appear too confusing for more
omplex cases, the Structures Group Diagrams may then be
referable and simpler to analyze providing the same global
esult. Moreover, the global plan score will complement the
nformation provided by the radar plots quantifying the qual-
ty of the best plan by incorporating the dose prescription and
olerances deﬁned for all target volumes and OARs.6. Conclusions
A graphical method for comparison and assessment of the
quality of radiation therapy plans was developed. A clinical
planning case of the nasal cavity was used to illustrate its
operationality, functionalities and potential. Due to its sim-
plicity and ﬂexibility, SPIDERplan can be applied to all types
of radiotherapy delivery techniques. The graphical informa-
tion generated by the Structures Plan, the Group Plan and
the Structures Group Diagrams complemented by the global
plan score enables a fast and intuitive plan quality assessment
incorporating all clinical priorities and criteria established for
treatment plan approval.
Following the local clinical practice, the complete list of
clinical planning aims needs to be translated into SPIDER-
plan inputs. These may be established in terms of dose
prescription, PTV coverage and conformity, dose tolerance to
OARs, dose–volume conditions, etc. The customization pro-
cess must be clinically validated by comparing the results of
the SPIDERplan assessmentwith the radiation oncologist eval-
uation. This tuning phase will conﬁrm consistency with the
processing data of SPIDERplan.
It was demonstrated that SPIDERplan can be used as a
useful tool for supporting clinical plan approval with full cus-
tomization potential to any local clinical practice. After the
clinician realizes that his/her priorities and goals are fully
reﬂected in the graphics and scores, SPIDERplan can easily be
adopted with a very steep learning curve.
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